Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation

Completed · Phase 2

Conditions studied: Graft Versus Host Disease, GVHD

In brief

The purpose of this study is to extend the use of Tacrolimus and Sirolimus to determine how effective it is in preventing graft versus host disease (GVHD)in patients that have received non-myeloablative peripheral blood stem cell transplantation.

Key facts

Study ID

NCT00282282

Run by

Dana-Farber Cancer Institute

People needed

31

Starts

2006-01-01

Expected to finish

2009-07-01

Last updated by the study team

2014-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with hematologic malignancies who are at a high risk of complications after conventional transplantation
• Availability of a related donor who is identical at 6 HLA loci
• Greater than 18 years of age
• Performance status 0-2
• Life expectancy of > 100 days

You may not qualify if…

• Pregnancy
• Evidence of HIV infection
• Heart failure uncontrolled medication
• Total bilirubin > 2.0mg/dl that is due to hepatocellular dysfunction
• AST >90
• Serum Creatinine >2.0
• Cholesterol > 300mg/dl while adequately treated

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.